scholarly journals Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

2020 ◽  
Vol 98 (4) ◽  
pp. 355-367 ◽  
Author(s):  
Alessandro Nini ◽  
Michèle Janine Hoffmann ◽  
Rita Lampignano ◽  
Robert große Siemer ◽  
Guus Dalum ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Carcinoma Cells ◽  
Her2 Expression

scholarly journals Circulating tumor cells promote the metastatic colonization of disseminated carcinoma cells by inducing systemic inflammation

Oncotarget ◽  
2017 ◽  
Vol 8 (17) ◽  
pp. 28418-28430 ◽  
Author(s):  
Yong-Chao Li ◽  
Jiu-Ming Zou ◽  
Chao Luo ◽  
Yu Shu ◽  
Jing Luo ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Systemic Inflammation ◽  
Carcinoma Cells ◽  
Metastatic Colonization

scholarly journals Detection and HER2 Expression of Circulating Tumor Cells in Advanced Gastric Cancer Patients

2012 ◽  
Vol 23 ◽  
pp. xi118
Author(s):  
S. Matsusaka ◽  
K. Chin ◽  
M. Ogur ◽  
E. Shinozaki ◽  
M. Suenaga ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Her2 Expression ◽  
Gastric Cancer Patients

scholarly journals HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Afroditi Nanou ◽  
Leonie Laura Zeune ◽  
Francois-Clement Bidard ◽  
Jean-Yves Pierga ◽  
Leonardus Wendelinus Mathias Marie Terstappen
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Extracellular Vesicles ◽  
Metastatic Breast ◽  
Her2 Expression

Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 11043-11043 ◽  
Author(s):  
Julia Katharina Neugebauer ◽  
Brigitte Kathrin Rack ◽  
Bernadette Anna Sophia Jaeger ◽  
Ulrich Andergassen ◽  
Aurelia Pestka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Her2 Status ◽  
Her2 Overexpression ◽  
Her2 Expression ◽  
Her2 Positive ◽  
Before And After

11043 Background: The discordance between HER2-expression on circulating tumor cells (CTC) in peripheral blood and the primary tumor has already been shown by our study group for early breast cancer patients with HER2-positive tumors. Here, we compare the results to CTC prevalence and HER2-status of CTC after adjuvant chemotherapy. Methods: The SUCCESS B trial compares FEC-Docetaxel vs. FEC-Docetaxel-Gemcitabine and HER2-targeted therapy as adjuvant treatment for patients with early, HER2-positive, node positive or high risk node negative primary breast cancer. We prospectively analyzed 23ml peripheral blood before and after chemotherapy. CTC and HER2-status were assessed with the CellSearchSystem (Veridex, USA). After immunomagnetic enrichment with an anti-Epcam-antibody, cells were labeled with anti-CK 8/18/19, anti-CD45 antibodies as well as a fluorescein conjugate antibody for HER2-phenotyping. Cutoff for CTC positivity was ≥ 1 CTC. HER-positivity of CTC was assigned if at least one CTC showed strong HER2 staining (3+). Results: CTCs and their HER2-status both before and after chemotherapy were available for 392 patients. In 179 (45.7%) patients no CTC were detected before and after chemotherapy. CTC status changed from positive before to negative after chemotherapy in 104 (26.5%) patients and from negative before to positive after chemotherapy in 69 (17.6%) patients, while 40 (10.2%) patients had a consistently positive CTC status. Patients were significantly more likely to change their CTC status from positive to negative than from negative to positive (p = 0.01). Of the 40 patients with CTC both before and after chemotherapy, 14 (35%) patients had HER2-positive CTC before and after therapy, and 9 (22%) patients had HER2-negative CTC at both time points. 7 (18%) patients had HER2-positive CTC before but not after chemotherapy, while 10 (25%) patients showed the reverse pattern (p = 0.63). Conclusions: Cytotoxic treatment does not seem to influence the HER2-status on CTC. Follow-up data within the Success B trial will analyze the relevance of the HER2-expression of CTC to predict the efficacy of targeted treatment.

Sign in / Sign up

Export Citation Format

Share Document